News

The U.S. Food and Drug Administration has approved Medtronic’s Implantable System for Remodulin, or ISR, to deliver Remodulin to patients with pulmonary arterial hypertension (PAH). PAH patients have high blood pressure in their pulmonary arteries, those that carry blood from the heart to the lungs, which can cause damage to…

Patients with pulmonary hypertension have little daily exercise, often at levels so low their their odds of survival are reduced, according to researchers. Their study, “Physical activity levels are low in patients with pulmonary hypertension,” was published in the journal Annals of Translational Medicine. International guidelines recommend…

SOX17 may be a risk gene that contributes to pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD), as well as to idiopathic and/or familial PAH, according to researchers. Their study, “Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital…

Pulmonary hypertension (PH) patients who underwent weight loss surgery were able to lose a significant amount of weight and showed improvements in lung function, a study reports. The study, “Bariatric surgery in patients with pulmonary hypertension,” was published in the journal Surgery for Obesity and Related Diseases.

Three years ago, Miloš Lazić taught physical education at a Belgrade elementary school while playing for Serbia’s championship water polo team. These days, Lazić is still a teacher — but he can barely take 10 steps without getting out of breath. Lazić, a big, muscular 37-year-old with tattoos on his biceps, has…

Adempas therapy significantly improves lung and heart function in patients with chronic thromboembolic pulmonary hypertension (CTEPH) previously treated off-label with sildenafil, according to a Polish study. The study reporting the findings, “Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves…

Blood biomarkers may help to predict poor outcomes in babies born with a rare congenital defect of the diaphragm that often leads to pulmonary hypertension (PH). The seven biomarkers, identified by researchers in Germany and evident in the blood within 24 hours of birth, were associated with a…

Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) and their caregivers can now access myMentor, a U.S. support program established by Bayer. The company launched the program at the International PH Conference and Scientific Sessions that recently concluded in Orlando, Florida, and was organized by…

Pulmonary arterial hypertension (PAH) affects the health of the gut’s microbial community, or microbiota, with an imbalance possibly being a factor in disease progression, a small study performed in a rat PAH model reports. The study, “Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome,” was published in the…

An enzyme called NOX4 appears to have a crucial role in the blood vessel remodeling that can lead to pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD), a study in China reports. The research, “NOX4 expression and distal arteriolar remodeling correlate with pulmonary hypertension…

Adempas (riociguat), an approved therapy for adults with pulmonary hypertension (PH), may hold promise for treating newborns with bronchopulmonary dysplasia (BPD) and PH, results of an animal study show. These findings suggest that Adempas’ use in babies…

Vivus Biopharmaceuticals’ investigative therapy VI-0106 for pulmonary arterial hypertension (PAH) showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial. Pharmacokinetics refers to how a medication is absorbed, distributed, metabolized, and eliminated from the body. VI-0106 is a soft gel formulation of tacrolimus, an immunosuppressant under…